Pancreatic Cancer Research

ResearcherUniversity of MissouriActive in the last 2 years

Satyanarayana Rachagani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3949-8566; OpenAlex author ID A5002662464; NIH RePORTER profile ID 10213657. Sources: OpenAlex.

Their work

Papers
63 (first author 10, last author 9)
Trials
0
Grants
2
Labs led
2
Collaborators
123
Papers, trials and grants by year

2011: 3 papers · 2012: 4 papers · 2013: 4 papers · 2014: 3 papers · 2015: 9 papers · 2016: 7 papers · 2017: none · 2018: 4 papers · 2019: 4 papers · 2020: 4 papers, 1 grant · 2021: 11 papers · 2022: 5 papers · 2023: 2 papers · 2024: 1 paper, 1 grant · 2025: 2 papers

Papers 50 of 63

  1. Niclosamide-Loaded Polyanhydride Nanoparticles to Combat Gemcitabine Resistance in Pancreatic Cancer. Last author DOI 10.1007/s40883-025-00394-0↗
  2. Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition. Last author DOI 10.1016/j.isci.2025.114088↗
  3. Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00562-5↗
  4. Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. Co-author DOI 10.1038/s41388-022-02587-1↗
  5. Histidine Enhances the Anticancer Effect of Gemcitabine against Pancreatic Cancer via Disruption of Amino Acid Homeostasis and Oxidant-Antioxidant Balance. First author DOI 10.3390/cancers15092593↗
  6. Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215801↗
  7. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. Co-author DOI 10.1016/j.ebiom.2021.103772↗
  8. Reduction in O-glycome induces differentially glycosylated CD44 to promote stemness and metastasis in pancreatic cancer. Co-author DOI 10.1038/s41388-021-02047-2↗
  9. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-022-02493-6↗
  10. Ubiquitous Aberration in Cholesterol Metabolism across Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/metabo12010047↗
  11. Nuclear factor kappa-B contributes to cigarette smoke tolerance in pancreatic ductal adenocarcinoma through cysteine metabolism. Last author DOI 10.1016/j.biopha.2021.112312↗
  12. Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2020.11.029↗
  13. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-020-01518-2↗
  14. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-020-01564-w↗
  15. MASTL regulates EGFR signaling to impact pancreatic cancer progression. Co-author DOI 10.1038/s41388-021-01951-x↗
  16. Secretory Mucin 5AC Promotes Neoplastic Progression by Augmenting KLF4-Mediated Pancreatic Cancer Cell Stemness. Co-author DOI 10.1158/0008-5472.can-20-1293↗
  17. Plexin-B3 Regulates Cellular Motility, Invasiveness, and Metastasis in Pancreatic Cancer. Co-author DOI 10.3390/cancers13040818↗
  18. Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of a Spontaneous Mouse Model of Pancreatic… Co-author DOI 10.3390/cancers13071535↗
  19. Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β. Last author DOI 10.3390/cancers13133105↗
  20. Correction: Kaushal et al. Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β. Cancers 2021, 13, 3105. Last author DOI 10.3390/cancers13225591↗
  21. Emerging Role of miR-345 and Its Effective Delivery as a Potential Therapeutic Candidate in Pancreatic Cancer and Other Cancers. Last author DOI 10.3390/pharmaceutics13121987↗
  22. Global analysis of human glycosyltransferases reveals novel targets for pancreatic cancer pathogenesis. Co-author DOI 10.1038/s41416-020-0772-3↗
  23. RNA Polymerase II-Associated Factor 1 Regulates Stem Cell Features of Pancreatic Cancer Cells, Independently of the PAF1 Complex, via Interactions With PHF5A a… Co-author DOI 10.1053/j.gastro.2020.07.053↗
  24. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Co-author DOI 10.1096/fj.201902990r↗
  25. Acinar transformed ductal cells exhibit differential mucin expression in a tamoxifen-induced pancreatic ductal adenocarcinoma mouse model. Last author DOI 10.1242/bio.052878↗
  26. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2019.03.056↗
  27. Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer. Last author DOI 10.1016/j.jconrel.2018.12.031↗
  28. MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention. Co-author DOI 10.1016/j.semcancer.2017.11.020↗
  29. Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition. Co-author DOI 10.1016/j.trsl.2018.12.008↗
  30. Cigarette Smoke Induces Stem Cell Features of Pancreatic Cancer Cells via PAF1. Co-author DOI 10.1053/j.gastro.2018.05.041↗
  31. Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells. Co-author DOI 10.1186/s12885-018-5074-2↗
  32. Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting. First author DOI 10.1186/s13046-018-0963-4↗
  33. Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis. Co-author DOI 10.18632/oncotarget.23644↗
  34. Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis. Co-author DOI 10.1016/j.biomaterials.2016.05.042↗
  35. The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.molonc.2015.10.005↗
  36. Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer. Co-author DOI 10.1016/j.molonc.2016.04.007↗
  37. PR55α Subunit of Protein Phosphatase 2A Supports the Tumorigenic and Metastatic Potential of Pancreatic Cancer Cells by Sustaining Hyperactive Oncogenic Signal… Co-author DOI 10.1158/0008-5472.can-15-2119↗
  38. MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism. Co-author DOI 10.18632/genesandcancer.104↗
  39. Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.6580↗
  40. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer. Co-author DOI 10.18632/oncotarget.6906↗
  41. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Co-author DOI 10.1016/j.addr.2014.10.020↗
  42. Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages. Co-author DOI 10.1038/onc.2014.154↗
  43. NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer. Co-author DOI 10.1038/onc.2014.409↗
  44. Amyloid precursor-like protein 2 (APLP2) affects the actin cytoskeleton and increases pancreatic cancer growth and metastasis. First author DOI 10.18632/oncotarget.2990↗
  45. Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.3286↗
  46. Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells. First author DOI 10.18632/oncotarget.3308↗
  47. Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.3912↗
  48. Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model. Co-author DOI 10.18632/oncotarget.5641↗
  49. Significance of microRNA-based biomarkers for pancreatic cancer. Co-author DOI 10.3978/j.issn.2305-5839.2015.10.32↗
  50. Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells. Co-author DOI 10.1038/bjc.2014.152↗

Grants 2

  1. Targeting tumor and its microenvironment using nanotherapeutics for pancreatic cancer R01CA247763↗
  2. Altered Histidine Metabolism in Pancreatic Cancer: A Novel Metabolic Target to Enhance Gemcitabine Efficacy R21CA238953↗

Closest collaborators

The 25 strongest of 123 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Surinder K. Batra · 61 shared papers, 2011–2025 · strength 5.29
  2. Moorthy Palanimuthu Ponnusamy · 28 shared papers, 2011–2024 · strength 2.22
  3. Parthasarathy Seshacharyulu · 16 shared papers, 2012–2024 · strength 1.41
  4. Lynette M. Smith · 18 shared papers, 2011–2024 · strength 1.33
  5. Maneesh Jain · 16 shared papers, 2011–2024 · strength 1.25
  6. Sushil Kumar K · 13 shared papers, 2011–2024 · strength 1.04
  7. Sanchita Rauth · 9 shared papers, 2018–2024 · strength 0.97
  8. Rama Krishna Nimmakayala · 9 shared papers, 2018–2022 · strength 0.95
  9. Nagabhishek Sirpu Natesh · 5 shared papers, 2021–2025 · strength 0.93
  10. Pranita Atri · 8 shared papers, 2018–2024 · strength 0.86
  11. Kavita B. Mallya · 9 shared papers, 2011–2022 · strength 0.82
  12. Venugopal Gunda · 4 shared papers, 2021–2025 · strength 0.76
  13. Jesse L. Cox · 5 shared papers, 2021–2024 · strength 0.71
  14. Sukhwinder Kaur · 12 shared papers, 2011–2022 · strength 0.68
  15. Saswati Karmakar · 7 shared papers, 2016–2022 · strength 0.66
  16. Palanisamy Nallasamy · 6 shared papers, 2020–2022 · strength 0.66
  17. Brianna M. White · 3 shared papers, 2021–2025 · strength 0.63
  18. Seema Chugh · 7 shared papers, 2015–2022 · strength 0.61
  19. Jyoti Kaushal · 4 shared papers, 2021–2023 · strength 0.60
  20. Imayavaramban Lakshmanan · 10 shared papers, 2011–2022 · strength 0.56
  21. Dhanya Haridas · 10 shared papers, 2011–2022 · strength 0.55
  22. Geoffrey A. Talmon · 5 shared papers, 2018–2022 · strength 0.54
  23. Koelina Ganguly · 4 shared papers, 2019–2024 · strength 0.52
  24. Balaji Narasimhan · 2 shared papers, 2025 · strength 0.49
  25. Susheel Kumar Nethi · 2 shared papers, 2025 · strength 0.49

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.